This study investigates the safety of non-surgical periodontal treatment during long-term low-dose aspirin therapy in patients with chronic periodontitis and gynaecological conditions, focusing on bleeding risk and coagulation function. Patients received low-dose aspirin (100 mg/d) and were divided into a medication continuation group (observation) and a cessation group (control), with 41 patients each. Key periodontal parameters (plaque index, probing depth, attachment loss) and coagulation indices (activated partial thromboplastin time, prothrombin time, thrombin time, prothrombin activity) were assessed post-treatment. Results showed no significant difference in coagulation indices and bleeding scores between the groups (P > 0.05). Grade 3 bleeding incidents were slightly higher in the observation group but not statistically significant. The observation group's maximum platelet aggregation rate was significantly lower (P < 0.0001), with no significant differences in activated partial thromboplastin time, prothrombin time, thrombin time, or prothrombin activity. The findings suggest that non-surgical periodontal treatment is safe for these patients under long-term low-dose aspirin therapy, with limited increased bleeding risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.29063/ajrh2025/v29i1.16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dual antiplatelet pre-treatment with aspirin and ticagrelor in ACS patients undergoing unplanned aortocoronary bypass surgery.
Clin Res Cardiol
March 2025
Department of Internal Medicine III, Cardiology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Background: Major bleedings following coronary artery bypass grafting (CABG) have significant implications on outcomes in acute coronary syndrome (ACS) patients. Owing fears of fatal bleedings in case of urgent CABG, current guidelines recommend a cessation of P2Y receptor antagonists (P2Y-RA) before cardiac surgery and opt against routine pre-treatment with a P2Y-RA before coronary angiography (CA). However, sparse information exists outside randomized trials on the frequency of urgent CABG and the consequences of inappropriately long cessation of P2Y-RA treatment in patients presenting with ACS.
View Article and Find Full Text PDFBedtime vs. morning aspirin intake on the diurnal variability of blood pressure and platelet aggregation for the prevention of coronary artery diseases: a systematic review and meta-analysis.
Acta Cardiol
March 2025
Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Purpose: Low-dose aspirin had been widely used for secondary prevention of cardiovascular disease. Chronopharmacology of arterial hypertension and platelet aggregation impacts the long-term thromboembolic risk in patients with cardiovascular disease. Therefore, clinical studies have proposed optimising aspirin dosing time.
View Article and Find Full Text PDFComparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study.
Diabetes Res Clin Pract
March 2025
Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom; Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China; Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address:
Aims: To compare the effects of low-dose aspirin and clopidogrel on the risk of incident type 2 diabetes among patients with ASCVD.
Methods: This target trial emulation study was performed usingthe IQVIA Medical Research Data UK primary care database, including adults with an incident first ASCVD event who initiated low-dose aspirin or clopidogrel between 2004 and 2021. We applied an overlap weighting approach to balance treatment groups.
Insights on DAPT Abbreviation and De-escalation from ULTIMATE-DAPT and Related Trials: Are we Heading Toward an Aspirin-Free Strategy?
Am J Cardiovasc Drugs
March 2025
Department of Cardiology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, UP, 226014, India.
The results of the recently concluded ULTIMATE-DAPT and T-PASS trials strongly support the emerging concept of antiplatelet monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention. Monotherapy with more potent antiplatelets such as ticagrelor is both a safe and an equally effective strategy to circumvent major bleeding episodes in patients at high bleeding risk while guarding against ischemic events. Although these results were not replicated with low-dose prasugrel monotherapy in the STOP-DAPT-3 trial, the other major trials investigating ticagrelor monotherapy (GLOBAL-LEADERS and TWILIGHT-ACS) suggested the feasibility and appropriateness of abbreviating the dual antiplatelet therapy (DAPT) as early as 1-3 months of the index procedure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!